298 related articles for article (PubMed ID: 7903204)
41. A convenient cancer vaccine therapy with in vivo transfer of interleukin 12 expression plasmid using gene gun technology after priming with irradiated carcinoma cells.
Nishitani MA; Sakai T; Ishii K; Zhang M; Nakano Y; Nitta Y; Miyazaki J; Kanayama HO; Kagawa S; Himeno K
Cancer Gene Ther; 2002 Feb; 9(2):156-63. PubMed ID: 11857033
[TBL] [Abstract][Full Text] [Related]
42. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma.
Nakano H; Kishida T; Asada H; Shin-Ya M; Shinomiya T; Imanishi J; Shimada T; Nakai S; Takeuchi M; Hisa Y; Mazda O
J Gene Med; 2006 Jan; 8(1):90-9. PubMed ID: 16097036
[TBL] [Abstract][Full Text] [Related]
43. Plasmid DNA gene therapy: studies with the human interleukin-2 gene in tumor cells in vitro and in the murine B16 melanoma model in vivo.
Parker SE; Khatibi S; Margalith M; Anderson D; Yankauckas M; Gromkowski SH; Latimer T; Lew D; Marquet M; Manthorpe M; Hobart P; Hersh E; Stopeck AT; Norman J
Cancer Gene Ther; 1996; 3(3):175-85. PubMed ID: 8725882
[TBL] [Abstract][Full Text] [Related]
44. Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity.
Hwang KS; Cho WK; Yoo J; Seong YR; Kim BK; Kim S; Im DS
Cancer Gene Ther; 2004 Jun; 11(6):397-407. PubMed ID: 15044962
[TBL] [Abstract][Full Text] [Related]
45. Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreted by cDNA-transfected tumor cells induces a more potent antitumor response than exogenous GM-CSF.
Shi FS; Weber S; Gan J; Rakhmilevich AL; Mahvi DM
Cancer Gene Ther; 1999; 6(1):81-8. PubMed ID: 10078967
[TBL] [Abstract][Full Text] [Related]
46. Antitumor activity and immune enhancement of murine interleukin-23 expressed in murine colon carcinoma cells.
Shan BE; Hao JS; Li QX; Tagawa M
Cell Mol Immunol; 2006 Feb; 3(1):47-52. PubMed ID: 16549049
[TBL] [Abstract][Full Text] [Related]
47. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.
Redlinger RE; Mailliard RB; Lotze MT; Barksdale EM
J Pediatr Surg; 2003 Mar; 38(3):301-7; discussion 301-7. PubMed ID: 12632339
[TBL] [Abstract][Full Text] [Related]
48. Injection of complementary DNA encoding interleukin-12 inhibits tumor establishment at a distant site in a murine renal carcinoma model.
Tan J; Newton CA; Djeu JY; Gutsch DE; Chang AE; Yang NS; Klein TW; Hua Y
Cancer Res; 1996 Aug; 56(15):3399-403. PubMed ID: 8758901
[TBL] [Abstract][Full Text] [Related]
49. Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells.
Abdel-Wahab Z; Dar MM; Hester D; Vervaert C; Gangavalli R; Barber J; Darrow TL; Seigler HF
Cell Immunol; 1996 Aug; 171(2):246-54. PubMed ID: 8806794
[TBL] [Abstract][Full Text] [Related]
50. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells.
Wolf SF; Temple PA; Kobayashi M; Young D; Dicig M; Lowe L; Dzialo R; Fitz L; Ferenz C; Hewick RM
J Immunol; 1991 May; 146(9):3074-81. PubMed ID: 1673147
[TBL] [Abstract][Full Text] [Related]
51. Local conditions in the host influence immunotherapy with interleukin-2 and LAK cells.
Steller EP; Ottow RT; Eggermont AM; Marquet RL; Sugarbaker PH
Cancer Detect Prev; 1988; 12(1-6):81-90. PubMed ID: 3263202
[TBL] [Abstract][Full Text] [Related]
52. Murine models of cancer cytokine gene therapy using interleukin-12.
Tahara H; Zitvogel L; Storkus WJ; Robbins PD; Lotze MT
Ann N Y Acad Sci; 1996 Oct; 795():275-83. PubMed ID: 8958939
[TBL] [Abstract][Full Text] [Related]
53. Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors.
Karasuyama H; Melchers F
Eur J Immunol; 1988 Jan; 18(1):97-104. PubMed ID: 2831066
[TBL] [Abstract][Full Text] [Related]
54. High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12.
Meko JB; Yim JH; Tsung K; Norton JA
Cancer Res; 1995 Nov; 55(21):4765-70. PubMed ID: 7585501
[TBL] [Abstract][Full Text] [Related]
55. Eosinophils infiltrating interleukin-5 gene-transfected tumors do not suppress tumor growth.
Krüger-Krasagakes S; Li W; Richter G; Diamantstein T; Blankenstein T
Eur J Immunol; 1993 Apr; 23(4):992-5. PubMed ID: 8458388
[TBL] [Abstract][Full Text] [Related]
56. Adjuvant immunotherapy using fibroblasts genetically engineered to secrete interleukin 12 prevents recurrence after surgical resection of established tumors in a murine adenocarcinoma model.
Matsumoto G; Sunamura M; Shimamura H; Kodama T; Hashimoto W; Kobari M; Kato K; Takeda K; Yagita H; Okumura K; Hamada H; Matsuno S
Surgery; 1999 Mar; 125(3):257-64. PubMed ID: 10076609
[TBL] [Abstract][Full Text] [Related]
57. Cytokine gene therapy of mesothelioma. Immune and antitumor effects of transfected interleukin-12.
Caminschi I; Venetsanakos E; Leong CC; Garlepp MJ; Robinson BW; Scott B
Am J Respir Cell Mol Biol; 1999 Sep; 21(3):347-56. PubMed ID: 10460752
[TBL] [Abstract][Full Text] [Related]
58. In vivo enhancement of antitumor immunity by interleukin 2-rich lymphokines.
O'Donnell RW; Marquis DM; Mudholkar GS; McCune CS
Cancer Res; 1986 Jul; 46(7):3273-8. PubMed ID: 3011244
[TBL] [Abstract][Full Text] [Related]
59. Interleukin-21 restrains tumor growth and induces a substantial increase in the number of circulating tumor-specific T cells in a murine model of malignant melanoma.
Petersen CC; Diernaes JE; Skovbo A; Hvid M; Deleuran B; Hokland M
Cytokine; 2010 Jan; 49(1):80-8. PubMed ID: 19962321
[TBL] [Abstract][Full Text] [Related]
60. Effects on apoptosis and cell cycle arrest contribute to the antitumor responses of interleukin-27 mediated by retrovirus in human pancreatic carcinoma cells.
Liu L; Meng J; Zhang C; Duan Y; Zhao L; Wang S; Shan B
Oncol Rep; 2012 May; 27(5):1497-503. PubMed ID: 22293948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
